The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis

被引:25
|
作者
Gupta, Samir K. [1 ]
Rosenkranz, Susan L. [2 ]
Cramer, Yoninah S. [2 ]
Koletar, Susan L. [3 ]
Szczech, Lynda A. [4 ]
Amorosa, Valerianna [5 ]
Hall, Stephen D. [1 ]
机构
[1] Indiana Univ, Sch Med, Indianapolis, IN USA
[2] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Univ Penn, Philadelphia, PA 19104 USA
关键词
dialysis; efavirenz; HIV; lopinavir; pharmacogenomics; pharmacokinetics; renal failure; ritonavir;
D O I
10.1097/QAD.0b013e32830e011f
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate the pharmacokinetics and pharmacogenomics of efavirenz (EFV) and lopinavir/ritonavir (LPV/RTV) in HIV-infected persons requiring hemodialysis. Design: Prospective, observational study of HIV-infected hemodialysis patients receiving one 600 mg tablet daily of EFV (N = 13) or three 133.3/33.3 mg capsules twice daily of LPV/RTV (N = 13). Methods: Twenty-four-hour EFV and 12-h LPV/RTV pharmacokinetics were assessed. Geometric mean ratios were calculated using historical controls with normal renal function. The effects of several candidate gene polymorphisms were also explored. Results: The geometric mean [95% confidence interval (CI); percentage of coefficient of variation (% CV)] C-min, C-max, and area under the curve (AUC) for the EFV group were 1.81 mu g/ml (0.93, 3.53; 103%), 5.04 mu g/ml (3.48, 7.29; 72%), and 71.5 mu g h/ml (43.2, 118.3; 93%), respectively. These parameters were 2.76 mu g/ml (1.86, 4.11; 53%), 8.45 mu g/ml (6.41, 11.15; 52%), and 69.6 mu g h/ml (55.6, 87.2; 37%) for LPV and 0.08 mu g/ml (0.05, 0.14; 63%), 0.58 mu g/ml (0.44, 0.76; 41 %), and 3.74 mu g h/ml (2.91, 4.80; 37%) for RTV. The AUC geometric mean ratios (90% CI) for EFV, LPV, and RTV were 132% (89, 197), 81% (67, 97), and 92% (76, 111), respectively. LPV C-min was lower than expected in the hemodialysis group. Higher EFV concentrations were associated with the CYP2B6 516G > T polymorphism. Conclusion: The pharmacokinetics of EFV and LPV/RTV in hemodialysis suggests that no dosing adjustments are necessary in treatment-naive patients. As HIV-infected hemodialysis patients are disproportionately black, the increased frequency of the CYP2B6 516G > T polymorphism may lead to higher EFV levels. The potentially lower LPV trough levels in this population suggest that LPV/RTV should be used with caution in protease-inhibitor-experienced patients. (c) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:1919 / 1927
页数:9
相关论文
共 50 条
  • [1] Pharmacokinetics of Lopinavir/Ritonavir and Efavirenz in Food Insecure HIV-Infected Pregnant and Breastfeeding Women in Tororo, Uganda
    Bartelink, Imke H.
    Savic, Rada M.
    Mwesigwa, Julia
    Achan, Jane
    Clark, Tamara
    Plenty, Albert
    Charlebois, Edwin
    Kamya, Moses
    Young, Sera L.
    Gandhi, Monica
    Havlir, Diane
    Cohan, Deborah
    Aweeka, Francesca
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (02): : 121 - 132
  • [2] Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
    Lopez Aspiroz, Elena
    Santos Buelga, Dolores
    Cabrera Figueroa, Salvador
    Lopez Galera, Rosa Maria
    Ribera Pascuet, Esteban
    Dominguez-Gil Hurle, Alfonso
    Garcia Sanchez, Maria Jose
    THERAPEUTIC DRUG MONITORING, 2011, 33 (05) : 573 - 582
  • [3] Sex Differences in Lopinavir and Ritonavir Pharmacokinetics Among HIV-Infected Women and Men
    Umeh, Obi C.
    Currier, Judith S.
    Park, Jeong-Gun
    Cramer, Yoninah
    Hermes, Ashwaq E.
    Fletcher, Courtney V.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1665 - 1673
  • [4] Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients
    van der Lee, Manon
    Sankatsing, Roaj
    Schippers, Emile
    Vogel, Martin
    Faetkenheuer, Erd
    van der Ven, Andre
    Kroon, Frank
    Rockstroh, Juegen
    Wyen, Christoph
    Baeumer, Anselm
    de Root, Eric
    Koopmans, Peter
    Stroes, Erik
    Reiss, Peter
    Burger, David
    ANTIVIRAL THERAPY, 2007, 12 (07) : 1127 - 1132
  • [5] Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients
    Sandkovsky, Uriel
    Podany, Anthony T.
    Fletcher, Courtney V.
    Owen, Andrew
    Felton-Coleman, Angela
    Winchester, Lee C.
    Robertson, Kevin
    Swindells, Susan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (01) : 200 - 204
  • [6] Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets
    Decloedt, Eric H.
    McIlleron, Helen
    Smith, Peter
    Merry, Concepta
    Orrell, Catherine
    Maartens, Gary
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) : 3195 - 3200
  • [7] The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals
    Decloedt, E. H.
    van der Walt, J. S.
    McIlleron, H.
    Wiesner, L.
    Maartens, G.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (10) : 1194 - 1196
  • [8] Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
    Moultrie, Harry
    McIlleron, Helen
    Sawry, Shobna
    Kellermann, Tracy
    Wiesner, Lubbe
    Kindra, Gurpreet
    Gous, Hermien
    Van Rie, Annelies
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (02) : 543 - 549
  • [9] Toxicogenetics of lopinavir/ritonavir in HIV-infected European patients
    Lopez Aspiroz, Elena
    Cabrera Figueroa, Salvador Enrique
    Cruz, Raquel
    Porras Hurtado, Gloria Liliana
    Fuertes Martin, Aurelio
    Dominguez-Gil Hurle, Alfonso
    Carracedo, Angel
    PERSONALIZED MEDICINE, 2014, 11 (03) : 263 - 272
  • [10] Simplification to lopinavir/ritonavir monotherapy in HIV-infected children
    Mur-Sierra, A.
    Lopez-Segura, N.
    Lopez-Vilchez, M. A.
    ANALES DE PEDIATRIA, 2011, 75 (01): : 51 - 54